Impaired Response to Interferon-α2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection
| Autor: | Silvano Gallus, Massimo Colombo, Guido Ronchi, Roberta D'Ambrosio, Ersilio Del Ninno, Alessio Aghemo, Roberta Soffredini, Maria Grazia Rumi |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pharmacology
Hepatitis medicine.medical_specialty Cirrhosis biology business.industry Hepatitis C virus Ribavirin Hepacivirus virus diseases Alpha interferon Hepatitis C medicine.disease_cause medicine.disease biology.organism_classification Gastroenterology chemistry.chemical_compound Liver disease Infectious Diseases chemistry Internal medicine Immunology medicine Pharmacology (medical) business |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 2040-2058 1359-6535 |
| DOI: | 10.1177/135965350601100602 |
| Popis: | Patients with chronic infection with the 3a genotype of hepatitis C virus (HCV) are considered as ‘easy-to-treat’ with interferon/ribavirin (IFN/RBV), independent of liver disease severity. However, patients with extensive fibrosis or cirrhosis were under-represented in all the registration Phase III trials performed so far. To assess the influence of liver fibrosis on the outcome of anti-HCV therapy, all patients with genotype 3a hepatitis C who were naive to IFN-based therapies, and received RBV combined with standard IFN or pegylated IFN-α2b (peg-IFN-α2b) as standard of care for their disease, were investigated at our centre. A sustained virological response (SVR) was achieved in 68 of 91 patients (75%) independent of IFN type, pretreatment viraemia, clearance of HCV RNA at week 4 and relevant co-morbidities. A SVR was less common in cirrhotics (6 of 17) than in non-cirrhotics (62 of 74; 35% vs 84%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|